Skip to main content
. 2023 Oct 16;15(20):5012. doi: 10.3390/cancers15205012

Figure 2.

Figure 2

The addition of VEGFi to a backbone of systemic therapy or BSC was associated with superior PFS. (A) Forest plot and pooled HRs for PFS comparing the backbone systemic therapy or BSC with versus without VEGFi (HR = 0.49; 95% CI, 0.40–0.61). (B) Forest plot and pooled HRs for PFS comparing the backbone systemic therapy or BSC with versus without VEGFi (HR = 0.59; 95% CI, 0.45–0.77) from studies that included patients with liver as the only site of metastasis. (C) Funnel plot showing high heterogeneity between all studies for PFS (I2 = 82%, p < 0.001) [18,27,28,30,31,32,33,34,35,36,37,39,40,41,42,45,48,49,50].